These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1776330)

  • 1. [Inhibition of platelet activation by endothelium-derived relaxing factor EDRF/NO and NO releasing dilator substances].
    Bassenge E
    Z Kardiol; 1991; 80 Suppl 5():17-21. PubMed ID: 1776330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors.
    Bassenge E
    Eur Heart J; 1991 Nov; 12 Suppl E():12-5. PubMed ID: 1665128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inhibition of thrombocyte aggregation and adhesion by endothelium-derived relaxant factor (EDRF) and their pathophysiologic significance].
    Bassenge E; Busse R; Pohl U
    Z Kardiol; 1989; 78 Suppl 6():54-8. PubMed ID: 2515672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo.
    Gerzer R; Drummer C; Karrenbrock B; Heim JM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S115-9. PubMed ID: 2484688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators.
    Salvemini D; Currie MG; Mollace V
    J Clin Invest; 1996 Jun; 97(11):2562-8. PubMed ID: 8647949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endothelial factors and thrombocyte function].
    Schrör K
    Z Kardiol; 1991; 80 Suppl 5():3-6. PubMed ID: 1776333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
    Maurice DH; Haslam RJ
    Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanisms and significance of the coupled release of endothelium-derived relaxing factor (EDRF) and prostacyclin (PGI2) from endothelial cells.
    Hyslop S; de Nucci G
    Wien Klin Wochenschr; 1991; 103(14):422-34. PubMed ID: 1926869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endothelium-derived relaxing factor(s): endogenous nitrates in the circulation?].
    Lüscher TF; Yang Z; Diederich D; Schneider K; von Segesser L; Siebenmann R; Stulz P; Bühler FR
    Schweiz Med Wochenschr; 1988 Nov; 118(46):1724-9. PubMed ID: 3062771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term exposure of endothelial cells to molsidomine increases their antithrombogenicity by inducing the production of nitric oxide-related chemical substances.
    Berenger-Bahuet FP; Rolland PH
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S98-105. PubMed ID: 2484710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
    Bult H; Fret HR; Herman AG
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.
    Palmer RM; Ferrige AG; Moncada S
    Nature; 1987 Jun 11-17; 327(6122):524-6. PubMed ID: 3495737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of platelet aggregation by endothelium-derived relaxing factor-like agents].
    Gerzer R; Karrenbrock B; Drummer C; Heim JM
    Med Klin (Munich); 1990 Feb; 85 Suppl 1():18-22. PubMed ID: 2185403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelium-derived relaxing and contracting factors.
    Vanhoutte PM; Eber B
    Wien Klin Wochenschr; 1991; 103(14):405-11. PubMed ID: 1926867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the effects of SIN-1, sodium nitroprusside and nitrate derivatives on the inhibition of blood platelet aggregation and activation of soluble platelet guanylate-cyclase].
    Karrenbrock B; Grewe R; Loeschke K; Gerzer R
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):251-4. PubMed ID: 2882462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelium-derived relaxing and contracting factors.
    Rubanyi GM
    J Cell Biochem; 1991 May; 46(1):27-36. PubMed ID: 1874796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived serotonin, the endothelium, and cardiovascular disease.
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S6-12. PubMed ID: 1717775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
    Mülsch A; Lückhoff A; Pohl U; Busse R; Bassenge E
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):119-25. PubMed ID: 2552329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nitric oxide: the endogenous nitrate in the cardiovascular system].
    Tschudi MR; Lüscher TF
    Herz; 1996 Jun; 21 Suppl 1():50-60. PubMed ID: 8767925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of endothelial cells for the regulation of the tone of smooth muscle--formation of an endothelial, relaxing factor].
    Förstermann U
    Z Kardiol; 1986 Oct; 75(10):577-83. PubMed ID: 2878541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.